Full text

Turn on search term navigation

© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Abstract

Background

Regular exercise has been shown to have beneficial health effects in cancer survivors, including improving quality of life and other important health outcomes. However, providing people with cancer with easily accessible, high-quality exercise support and programs is a challenge. Therefore, there is a need to develop easily accessible exercise programs that draw upon the current evidence. Supervised, distance-based exercise programs have the benefit of reaching out to many people whilst providing the support of an exercise professional. The aim of the EX-MED Cancer Sweden trial is to examine the effectiveness of a supervised, distance-based exercise program, in people previously treated for breast, prostate, or colorectal cancer, on health-related quality of life (HRQoL), as well as other physiological and patient-reported health outcomes.

Methods

The EX-MED Cancer Sweden trial is a prospective randomised controlled trial including 200 people that have completed curative treatment for breast, prostate, or colorectal cancer. Participants are randomly allocated to an exercise group or a routine care control group. The exercise group will participate in a supervised, distanced-based exercise program delivered by a personal trainer who has undertaken specialised exercise oncology education modules. The intervention consists of a combination of resistance and aerobic exercises with participants completing two 60-min sessions per week for 12 weeks. The primary outcome is HRQoL (EORTC QLQ-C30) assessed at baseline, 3- (end of intervention and primary endpoint) and 6-months post-baseline. Secondary outcomes are physiological (cardiorespiratory fitness, muscle strength, physical function, body composition) and patient-reported outcomes (cancer-related symptoms, fatigue, self-reported physical activity), and self-efficacy of exercise. Furthermore, the trial will explore and describe the experiences of participation in the exercise intervention.

Discussion

The EX-MED Cancer Sweden trial will provide evidence regarding the effectiveness of a supervised, distance-based exercise program for survivors of breast, prostate, and colorectal cancer. If successful, it will contribute to the implementation of flexible and effective exercise programs as part of the standard of care for people following cancer treatment, which is likely to contribute to a reduction in the burden of cancer on the individual, health care system and society.

Trial registration

www.ClinicalTrials.gov NCT05064670. Registered on October 1, 2021.

Details

Title
Distance-based delivery of exercise for people treated for breast, prostate or colorectal cancer: a study protocol for a randomised controlled trial of EX-MED Cancer Sweden
Author
Kotte, Melissa 1   VIAFID ORCID Logo  ; Bolam, Kate A. 2 ; Mijwel, Sara 3 ; Altena, Renske 4 ; Cormie, Prue 5 ; Wengström, Yvonne 6 

 Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); The Swedish School of Sport and Health Sciences, Department of Physical Activity and Health, Stockholm, Sweden (GRID:grid.416784.8) (ISNI:0000 0001 0694 3737) 
 Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Norwegian School of Sport Sciences, Department of Physical Performance, Oslo, Norway (GRID:grid.412285.8) (ISNI:0000 0000 8567 2092) 
 Karolinska University Hospital, Medical Unit Breast, Endocrine Tumors and Sarcoma, Theme Cancer, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705); Karolinska Institutet, Department of Oncology-Pathology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); The University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); EX-MED Cancer, Melbourne, Australia (GRID:grid.1008.9) 
 Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Medical Unit Breast, Endocrine Tumors and Sarcoma, Theme Cancer, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705) 
Pages
116
Publication year
2023
Publication date
Dec 2023
Publisher
BioMed Central
e-ISSN
17456215
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2777534682
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.